The purpose of the study is to collect blood from individuals who receive a licensed pneumococcal conjugate vaccine (PCV20, also known as Prevnar 20), for protection against invasive pneumococcal disease caused by a bacteria called Streptococcus pneumoniae (or S. pneumoniae).
In this study, we will test a new influenza vaccine called the “Flu pandemic mRNA (H5) vaccine”. This study will look into whether the new study vaccine is safe and how the human body reacts to it. This study vaccine has not been approved by the FDA. Thus, it is only given to people who participate in this study.
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension. We are doing this study to learn more about an investigational drug called Baxdrostat for treating high blood pressure that is not responding well enough to current treatment.
We are doing this study to learn more about an investigational drug called Baxdrostat for treating high blood pressure that is not responding well enough to current treatment. Hypertension is a serious condition that can cause several complications and may reduce your life expectancy if not treated appropriately. Baxdrostat has already been tested in participants with difficult-to-control high blood pressure in earlier research called “Phase 2” studies. Based on what we have learned in those studies about the potential for Baxdrostat to improve blood pressure levels, this Phase 3 study has been developed.
The purpose of this study is to collect blood (serum) or plasma from healthy people who have not been exposed to N. meningitides bacteria and do not have antibodies to the bacteria. Plasma and serum are the liquid parts of blood (that is, blood without the cells in it). The main difference between plasma and serum is that plasma has proteins that help blood clot, and serum does not. An antibody is a substance made by the immune system to fight infection. Both serum and plasma contain important components called complement proteins. These proteins together with the antibody are important for the immunity against infection-causing bacteria.
This study aims to collect blood (serum) or plasma that has suitable complement from donors for use in laboratory tests to measure antibody responses of subjects participating in studies where vaccines against N. meningitidis are administered. It’s hard to find donors who have human complement that can be used for these tests. Many adults have been exposed to N. meningitidis and already have antibodies in their blood, which prevent them from being eligible to donate plasma or blood (serum) for this study.
